 |
PRESS
RELEASES 
|
MOLOGEN AG appoints Dr. Stefan M. Manth to the scientific advisory board
Berlin, November 18, 2011 – The biotechnology company MOLOGEN AG has expanded its scientific advisory board. With Stefan M. Manth, MD, PhD, MBA, the advisory committee has been joined by a top manager from the pharmaceutical industry with extensive experience in the strategic development and marketing of innovative medicines.
Dr. Manth, who works as an independent consultant for pharmaceutical and biotechnology companies on operational issues and strategic matters, has previously workedfor over two decades for the Roche Group. He brings with him extensive international experience, and played an instrumental role in the successful development of the Oncology business at Roche/Genentech/Chugai. For MOLOGEN AG, whose first projects have entered advanced stages of clinical development, Dr. Manth’s professional background represents a crucial enrichment of the scientific advisory board’s portfolio of expertises. Prof. Dr. Burghardt Wittig, chairman of the scientific advisory board and co-founder of MOLOGEN AG, greatly welcomes the committee’s expansion. “We need the best to tackle the issues at hand to help MOLOGEN attain “best in class”-status. I am delighted that with Dr. Stefan Manth, we have, in this important first licensing phase, been able to access expertise that had been absent from our advisory board up to this point. Here, his competence with the strategic interdependence of scientific, clinical and regulatory issues is of enormous value to the scientific advisory board.” Dr. Stefan M. Manth: “It is a great pleasure and honor for me to work with the scientific advisory board of MOLOGEN AG and to advise and support a team of extraordinarily talented managers and researchers in their important mission. I am very enthusiastic about the, in my view, unique immunotherapeutic approach that MOLOGEN AG is taking to treat cancer. Three Nobel prizes for Medicine in 2011 are a truly excellent confirmation of this distinguished approach. In order to make it accessible to a large number of cancer patients, MOLOGEN AG has to successfully face and master all important challenges in the final phases of clinical development. I am happy to contribute my diverse experiences and knowledge to this endeavor.”
The scientific advisory board of MOLOGEN AG The scientific advisory board of MOLOGEN AG is a committee of respected, internationally acknowledged scientists in the fields of molecular medicine, infectious diseases and/or cancer diseases as well as experts in their field. It advises the Board of Directors on fundamental scientific procedures, new technologies and fields of business. It currently comprises five members:
www.mologen.com.
About MOLOGEN AG MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200).
Memberships in associations: BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE: Prof. Peter W. Huebner Head of Corporate Communications
INVESTOR RELATIONS: Joerg Petrass Tel: +49 - 30 - 84 17 88 - 13
External Investor Relations: Kirchhoff Consult AG Sebastian Bucher T: +49 - 40 - 60 91 86 - 18 F: +49 - 40 - 60 91 86 -16
Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation..
|
|
